The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Bevacizumab Injection Market Research Report 2025
Synopsis
The global Bevacizumab Injection market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Bevacizumab Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bevacizumab Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Bevacizumab Injection include Pfizer, Roche, Eli Lilly, Genentech, Bayer, Amgen, Samsung Bioepis, Centus and Cadila Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Bevacizumab Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bevacizumab Injection.
Report Scope
The Bevacizumab Injection market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bevacizumab Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bevacizumab Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Roche
Eli Lilly
Genentech
Bayer
Amgen
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Mylan
Hetero Group
Biocon
Segment by Type
100mg
400mg
Segment by Application
Age-related macular degeneration (AMD)
Ovarian Cancer
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bevacizumab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bevacizumab Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Bevacizumab Injection market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Bevacizumab Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bevacizumab Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Bevacizumab Injection include Pfizer, Roche, Eli Lilly, Genentech, Bayer, Amgen, Samsung Bioepis, Centus and Cadila Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Bevacizumab Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bevacizumab Injection.
Report Scope
The Bevacizumab Injection market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bevacizumab Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bevacizumab Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Roche
Eli Lilly
Genentech
Bayer
Amgen
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Mylan
Hetero Group
Biocon
Segment by Type
100mg
400mg
Segment by Application
Age-related macular degeneration (AMD)
Ovarian Cancer
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bevacizumab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bevacizumab Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Bevacizumab Injection Market Overview
1.1 Product Overview and Scope of Bevacizumab Injection
1.2 Bevacizumab Injection Segment by Type
1.2.1 Global Bevacizumab Injection Market Value Comparison by Type (2024-2030)
1.2.2 100mg
1.2.3 400mg
1.3 Bevacizumab Injection Segment by Application
1.3.1 Global Bevacizumab Injection Market Value by Application: (2024-2030)
1.3.2 Age-related macular degeneration (AMD)
1.3.3 Ovarian Cancer
1.3.4 Others
1.4 Global Bevacizumab Injection Market Size Estimates and Forecasts
1.4.1 Global Bevacizumab Injection Revenue 2019-2030
1.4.2 Global Bevacizumab Injection Sales 2019-2030
1.4.3 Global Bevacizumab Injection Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Bevacizumab Injection Market Competition by Manufacturers
2.1 Global Bevacizumab Injection Sales Market Share by Manufacturers (2019-2024)
2.2 Global Bevacizumab Injection Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Bevacizumab Injection Average Price by Manufacturers (2019-2024)
2.4 Global Bevacizumab Injection Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Bevacizumab Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bevacizumab Injection, Product Type & Application
2.7 Bevacizumab Injection Market Competitive Situation and Trends
2.7.1 Bevacizumab Injection Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Bevacizumab Injection Players Market Share by Revenue
2.7.3 Global Bevacizumab Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Bevacizumab Injection Retrospective Market Scenario by Region
3.1 Global Bevacizumab Injection Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Bevacizumab Injection Global Bevacizumab Injection Sales by Region: 2019-2030
3.2.1 Global Bevacizumab Injection Sales by Region: 2019-2024
3.2.2 Global Bevacizumab Injection Sales by Region: 2025-2030
3.3 Global Bevacizumab Injection Global Bevacizumab Injection Revenue by Region: 2019-2030
3.3.1 Global Bevacizumab Injection Revenue by Region: 2019-2024
3.3.2 Global Bevacizumab Injection Revenue by Region: 2025-2030
3.4 North America Bevacizumab Injection Market Facts & Figures by Country
3.4.1 North America Bevacizumab Injection Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Bevacizumab Injection Sales by Country (2019-2030)
3.4.3 North America Bevacizumab Injection Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bevacizumab Injection Market Facts & Figures by Country
3.5.1 Europe Bevacizumab Injection Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Bevacizumab Injection Sales by Country (2019-2030)
3.5.3 Europe Bevacizumab Injection Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bevacizumab Injection Market Facts & Figures by Country
3.6.1 Asia Pacific Bevacizumab Injection Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Bevacizumab Injection Sales by Country (2019-2030)
3.6.3 Asia Pacific Bevacizumab Injection Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Bevacizumab Injection Market Facts & Figures by Country
3.7.1 Latin America Bevacizumab Injection Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Bevacizumab Injection Sales by Country (2019-2030)
3.7.3 Latin America Bevacizumab Injection Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Bevacizumab Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Bevacizumab Injection Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Bevacizumab Injection Sales by Country (2019-2030)
3.8.3 Middle East and Africa Bevacizumab Injection Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bevacizumab Injection Sales by Type (2019-2030)
4.1.1 Global Bevacizumab Injection Sales by Type (2019-2024)
4.1.2 Global Bevacizumab Injection Sales by Type (2025-2030)
4.1.3 Global Bevacizumab Injection Sales Market Share by Type (2019-2030)
4.2 Global Bevacizumab Injection Revenue by Type (2019-2030)
4.2.1 Global Bevacizumab Injection Revenue by Type (2019-2024)
4.2.2 Global Bevacizumab Injection Revenue by Type (2025-2030)
4.2.3 Global Bevacizumab Injection Revenue Market Share by Type (2019-2030)
4.3 Global Bevacizumab Injection Price by Type (2019-2030)
5 Segment by Application
5.1 Global Bevacizumab Injection Sales by Application (2019-2030)
5.1.1 Global Bevacizumab Injection Sales by Application (2019-2024)
5.1.2 Global Bevacizumab Injection Sales by Application (2025-2030)
5.1.3 Global Bevacizumab Injection Sales Market Share by Application (2019-2030)
5.2 Global Bevacizumab Injection Revenue by Application (2019-2030)
5.2.1 Global Bevacizumab Injection Revenue by Application (2019-2024)
5.2.2 Global Bevacizumab Injection Revenue by Application (2025-2030)
5.2.3 Global Bevacizumab Injection Revenue Market Share by Application (2019-2030)
5.3 Global Bevacizumab Injection Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Bevacizumab Injection Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Bevacizumab Injection Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Roche
6.2.1 Roche Corporation Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Bevacizumab Injection Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Roche Bevacizumab Injection Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 Eli Lilly
6.3.1 Eli Lilly Corporation Information
6.3.2 Eli Lilly Description and Business Overview
6.3.3 Eli Lilly Bevacizumab Injection Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Eli Lilly Bevacizumab Injection Product Portfolio
6.3.5 Eli Lilly Recent Developments/Updates
6.4 Genentech
6.4.1 Genentech Corporation Information
6.4.2 Genentech Description and Business Overview
6.4.3 Genentech Bevacizumab Injection Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Genentech Bevacizumab Injection Product Portfolio
6.4.5 Genentech Recent Developments/Updates
6.5 Bayer
6.5.1 Bayer Corporation Information
6.5.2 Bayer Description and Business Overview
6.5.3 Bayer Bevacizumab Injection Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bayer Bevacizumab Injection Product Portfolio
6.5.5 Bayer Recent Developments/Updates
6.6 Amgen
6.6.1 Amgen Corporation Information
6.6.2 Amgen Description and Business Overview
6.6.3 Amgen Bevacizumab Injection Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Amgen Bevacizumab Injection Product Portfolio
6.6.5 Amgen Recent Developments/Updates
6.7 Samsung Bioepis
6.6.1 Samsung Bioepis Corporation Information
6.6.2 Samsung Bioepis Description and Business Overview
6.6.3 Samsung Bioepis Bevacizumab Injection Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Samsung Bioepis Bevacizumab Injection Product Portfolio
6.7.5 Samsung Bioepis Recent Developments/Updates
6.8 Centus
6.8.1 Centus Corporation Information
6.8.2 Centus Description and Business Overview
6.8.3 Centus Bevacizumab Injection Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Centus Bevacizumab Injection Product Portfolio
6.8.5 Centus Recent Developments/Updates
6.9 Cadila Pharmaceuticals
6.9.1 Cadila Pharmaceuticals Corporation Information
6.9.2 Cadila Pharmaceuticals Description and Business Overview
6.9.3 Cadila Pharmaceuticals Bevacizumab Injection Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Cadila Pharmaceuticals Bevacizumab Injection Product Portfolio
6.9.5 Cadila Pharmaceuticals Recent Developments/Updates
6.10 Dr Reddy's
6.10.1 Dr Reddy's Corporation Information
6.10.2 Dr Reddy's Description and Business Overview
6.10.3 Dr Reddy's Bevacizumab Injection Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Dr Reddy's Bevacizumab Injection Product Portfolio
6.10.5 Dr Reddy's Recent Developments/Updates
6.11 Mylan
6.11.1 Mylan Corporation Information
6.11.2 Mylan Bevacizumab Injection Description and Business Overview
6.11.3 Mylan Bevacizumab Injection Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Mylan Bevacizumab Injection Product Portfolio
6.11.5 Mylan Recent Developments/Updates
6.12 Hetero Group
6.12.1 Hetero Group Corporation Information
6.12.2 Hetero Group Bevacizumab Injection Description and Business Overview
6.12.3 Hetero Group Bevacizumab Injection Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Hetero Group Bevacizumab Injection Product Portfolio
6.12.5 Hetero Group Recent Developments/Updates
6.13 Biocon
6.13.1 Biocon Corporation Information
6.13.2 Biocon Bevacizumab Injection Description and Business Overview
6.13.3 Biocon Bevacizumab Injection Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Biocon Bevacizumab Injection Product Portfolio
6.13.5 Biocon Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bevacizumab Injection Industry Chain Analysis
7.2 Bevacizumab Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bevacizumab Injection Production Mode & Process
7.4 Bevacizumab Injection Sales and Marketing
7.4.1 Bevacizumab Injection Sales Channels
7.4.2 Bevacizumab Injection Distributors
7.5 Bevacizumab Injection Customers
8 Bevacizumab Injection Market Dynamics
8.1 Bevacizumab Injection Industry Trends
8.2 Bevacizumab Injection Market Drivers
8.3 Bevacizumab Injection Market Challenges
8.4 Bevacizumab Injection Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Bevacizumab Injection Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Bevacizumab Injection Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Bevacizumab Injection Market Competitive Situation by Manufacturers in 2023
Table 4. Global Bevacizumab Injection Sales (K Doses) of Key Manufacturers (2019-2024)
Table 5. Global Bevacizumab Injection Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Bevacizumab Injection Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Bevacizumab Injection Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Bevacizumab Injection Average Price (US$/Dose) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Bevacizumab Injection, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Bevacizumab Injection, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Bevacizumab Injection, Product Type & Application
Table 12. Global Key Manufacturers of Bevacizumab Injection, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Bevacizumab Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bevacizumab Injection as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Bevacizumab Injection Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Bevacizumab Injection Sales by Region (2019-2024) & (K Doses)
Table 18. Global Bevacizumab Injection Sales Market Share by Region (2019-2024)
Table 19. Global Bevacizumab Injection Sales by Region (2025-2030) & (K Doses)
Table 20. Global Bevacizumab Injection Sales Market Share by Region (2025-2030)
Table 21. Global Bevacizumab Injection Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Bevacizumab Injection Revenue Market Share by Region (2019-2024)
Table 23. Global Bevacizumab Injection Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Bevacizumab Injection Revenue Market Share by Region (2025-2030)
Table 25. North America Bevacizumab Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Bevacizumab Injection Sales by Country (2019-2024) & (K Doses)
Table 27. North America Bevacizumab Injection Sales by Country (2025-2030) & (K Doses)
Table 28. North America Bevacizumab Injection Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Bevacizumab Injection Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Bevacizumab Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Bevacizumab Injection Sales by Country (2019-2024) & (K Doses)
Table 32. Europe Bevacizumab Injection Sales by Country (2025-2030) & (K Doses)
Table 33. Europe Bevacizumab Injection Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Bevacizumab Injection Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Bevacizumab Injection Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Bevacizumab Injection Sales by Region (2019-2024) & (K Doses)
Table 37. Asia Pacific Bevacizumab Injection Sales by Region (2025-2030) & (K Doses)
Table 38. Asia Pacific Bevacizumab Injection Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Bevacizumab Injection Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Bevacizumab Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Bevacizumab Injection Sales by Country (2019-2024) & (K Doses)
Table 42. Latin America Bevacizumab Injection Sales by Country (2025-2030) & (K Doses)
Table 43. Latin America Bevacizumab Injection Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Bevacizumab Injection Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Bevacizumab Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Bevacizumab Injection Sales by Country (2019-2024) & (K Doses)
Table 47. Middle East & Africa Bevacizumab Injection Sales by Country (2025-2030) & (K Doses)
Table 48. Middle East & Africa Bevacizumab Injection Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Bevacizumab Injection Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Bevacizumab Injection Sales (K Doses) by Type (2019-2024)
Table 51. Global Bevacizumab Injection Sales (K Doses) by Type (2025-2030)
Table 52. Global Bevacizumab Injection Sales Market Share by Type (2019-2024)
Table 53. Global Bevacizumab Injection Sales Market Share by Type (2025-2030)
Table 54. Global Bevacizumab Injection Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Bevacizumab Injection Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Bevacizumab Injection Revenue Market Share by Type (2019-2024)
Table 57. Global Bevacizumab Injection Revenue Market Share by Type (2025-2030)
Table 58. Global Bevacizumab Injection Price (US$/Dose) by Type (2019-2024)
Table 59. Global Bevacizumab Injection Price (US$/Dose) by Type (2025-2030)
Table 60. Global Bevacizumab Injection Sales (K Doses) by Application (2019-2024)
Table 61. Global Bevacizumab Injection Sales (K Doses) by Application (2025-2030)
Table 62. Global Bevacizumab Injection Sales Market Share by Application (2019-2024)
Table 63. Global Bevacizumab Injection Sales Market Share by Application (2025-2030)
Table 64. Global Bevacizumab Injection Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Bevacizumab Injection Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Bevacizumab Injection Revenue Market Share by Application (2019-2024)
Table 67. Global Bevacizumab Injection Revenue Market Share by Application (2025-2030)
Table 68. Global Bevacizumab Injection Price (US$/Dose) by Application (2019-2024)
Table 69. Global Bevacizumab Injection Price (US$/Dose) by Application (2025-2030)
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Business Overview
Table 72. Pfizer Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 73. Pfizer Bevacizumab Injection Product
Table 74. Pfizer Recent Developments/Updates
Table 75. Roche Corporation Information
Table 76. Roche Description and Business Overview
Table 77. Roche Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 78. Roche Bevacizumab Injection Product
Table 79. Roche Recent Developments/Updates
Table 80. Eli Lilly Corporation Information
Table 81. Eli Lilly Description and Business Overview
Table 82. Eli Lilly Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 83. Eli Lilly Bevacizumab Injection Product
Table 84. Eli Lilly Recent Developments/Updates
Table 85. Genentech Corporation Information
Table 86. Genentech Description and Business Overview
Table 87. Genentech Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 88. Genentech Bevacizumab Injection Product
Table 89. Genentech Recent Developments/Updates
Table 90. Bayer Corporation Information
Table 91. Bayer Description and Business Overview
Table 92. Bayer Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 93. Bayer Bevacizumab Injection Product
Table 94. Bayer Recent Developments/Updates
Table 95. Amgen Corporation Information
Table 96. Amgen Description and Business Overview
Table 97. Amgen Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 98. Amgen Bevacizumab Injection Product
Table 99. Amgen Recent Developments/Updates
Table 100. Samsung Bioepis Corporation Information
Table 101. Samsung Bioepis Description and Business Overview
Table 102. Samsung Bioepis Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 103. Samsung Bioepis Bevacizumab Injection Product
Table 104. Samsung Bioepis Recent Developments/Updates
Table 105. Centus Corporation Information
Table 106. Centus Description and Business Overview
Table 107. Centus Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 108. Centus Bevacizumab Injection Product
Table 109. Centus Recent Developments/Updates
Table 110. Cadila Pharmaceuticals Corporation Information
Table 111. Cadila Pharmaceuticals Description and Business Overview
Table 112. Cadila Pharmaceuticals Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 113. Cadila Pharmaceuticals Bevacizumab Injection Product
Table 114. Cadila Pharmaceuticals Recent Developments/Updates
Table 115. Dr Reddy's Corporation Information
Table 116. Dr Reddy's Description and Business Overview
Table 117. Dr Reddy's Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 118. Dr Reddy's Bevacizumab Injection Product
Table 119. Dr Reddy's Recent Developments/Updates
Table 120. Mylan Corporation Information
Table 121. Mylan Description and Business Overview
Table 122. Mylan Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 123. Mylan Bevacizumab Injection Product
Table 124. Mylan Recent Developments/Updates
Table 125. Hetero Group Corporation Information
Table 126. Hetero Group Description and Business Overview
Table 127. Hetero Group Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 128. Hetero Group Bevacizumab Injection Product
Table 129. Hetero Group Recent Developments/Updates
Table 130. Biocon Corporation Information
Table 131. Biocon Description and Business Overview
Table 132. Biocon Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 133. Biocon Bevacizumab Injection Product
Table 134. Biocon Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Bevacizumab Injection Distributors List
Table 138. Bevacizumab Injection Customers List
Table 139. Bevacizumab Injection Market Trends
Table 140. Bevacizumab Injection Market Drivers
Table 141. Bevacizumab Injection Market Challenges
Table 142. Bevacizumab Injection Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Bevacizumab Injection
Figure 2. Global Bevacizumab Injection Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Bevacizumab Injection Market Share by Type in 2023 & 2030
Figure 4. 100mg Product Picture
Figure 5. 400mg Product Picture
Figure 6. Global Bevacizumab Injection Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Bevacizumab Injection Market Share by Application in 2023 & 2030
Figure 8. Age-related macular degeneration (AMD)
Figure 9. Ovarian Cancer
Figure 10. Others
Figure 11. Global Bevacizumab Injection Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Bevacizumab Injection Market Size (2019-2030) & (US$ Million)
Figure 13. Global Bevacizumab Injection Sales (2019-2030) & (K Doses)
Figure 14. Global Bevacizumab Injection Average Price (US$/Dose) & (2019-2030)
Figure 15. Bevacizumab Injection Report Years Considered
Figure 16. Bevacizumab Injection Sales Share by Manufacturers in 2023
Figure 17. Global Bevacizumab Injection Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Bevacizumab Injection Players: Market Share by Revenue in 2023
Figure 19. Bevacizumab Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Bevacizumab Injection Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Bevacizumab Injection Sales Market Share by Country (2019-2030)
Figure 22. North America Bevacizumab Injection Revenue Market Share by Country (2019-2030)
Figure 23. United States Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Bevacizumab Injection Sales Market Share by Country (2019-2030)
Figure 26. Europe Bevacizumab Injection Revenue Market Share by Country (2019-2030)
Figure 27. Germany Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Bevacizumab Injection Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Bevacizumab Injection Revenue Market Share by Region (2019-2030)
Figure 34. China Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. China Taiwan Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Bevacizumab Injection Sales Market Share by Country (2019-2030)
Figure 44. Latin America Bevacizumab Injection Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Bevacizumab Injection Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Bevacizumab Injection Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. UAE Bevacizumab Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Bevacizumab Injection by Type (2019-2030)
Figure 54. Global Revenue Market Share of Bevacizumab Injection by Type (2019-2030)
Figure 55. Global Bevacizumab Injection Price (US$/Dose) by Type (2019-2030)
Figure 56. Global Sales Market Share of Bevacizumab Injection by Application (2019-2030)
Figure 57. Global Revenue Market Share of Bevacizumab Injection by Application (2019-2030)
Figure 58. Global Bevacizumab Injection Price (US$/Dose) by Application (2019-2030)
Figure 59. Bevacizumab Injection Value Chain
Figure 60. Bevacizumab Injection Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
